HRS-4642 with chemo to shrink pancreatic cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a specific type of pancreatic cancer (ductal adenocarcinoma) that is locally advanced (has not spread to distant parts of the body).
- Your cancer has a specific gene change called KRAS G12D.
- You have not had any prior treatment for your cancer, such as chemotherapy or radiation.
- You are in good general health (able to care for yourself) with normal blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This study tests an experimental drug (HRS-4642) combined with other cancer treatments for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination is safe and effective.
Hear when a new Locally Advanced Pancreatic Cancer With KRAS G12D Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.